GlassScriptPhysician profile
Scott Kuykendall
NPI 1316933575
$9,810.65
in general payments reported to CMS, 2019-2025
40 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,610 · 2020: $1,456 · 2021: $1,491 · 2022: $1,238 · 2023: $1,360 · 2024: $1,461 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,921.10 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,604.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,477.95 | 2020-2025 | |
| Novo Nordisk INC | $982.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $831.34 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $607.61 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $538.00 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $501.64 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.44 | 2019-2025 | Jardiance |
| Pfizer INC. | $407.19 | 2019-2025 | |
| Abbott Laboratories | $253.03 | 2020-2024 | Freestyle Libre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.82 | 2022-2025 | Caplyta |
| Allergan, INC. | $230.26 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.62 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $157.40 | 2019-2023 | |
| Lilly USA, LLC | $134.81 | 2020-2025 | Mounjaro, Zepbound |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kuykendall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.